To examine the function of lesser-known gene fusions like CCDC32/CBX3 in AML, future gain or loss of function studies could also be executed to characterize subclonal evolution evolving treatment (Lee and Li, 2020). Here, CCDC32 is linked to acute myeloid leukemia.